Tonix Pharma (TNXP) Acquires Infectious Disease R&D Facility
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pre-Open Stock Movers 07/26: (TYME) (MSTR) (FLOW) Higher; (ATIP) (ITRM) (TNXP) Lower (more...)
July 26, 2021 9:29 AM EDTPre-Open Stock Movers:
Tyme Technologies, Inc. (NASDAQ: TYME) 54.6% HIGHER; announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Companys metabolomic technology platform. The patent, U.S. Patent No. 11,058,638, involves a targeted delivery of therapeutics to cancer cells.
ATI Physical Therapy (NYSE: ATIP) 41.3% LOWER; reported Q2 revenue of $164 million versus the consensus estimate of $175.37 million. For full year 2021, ATI is now... More
Tonix Pharma (TNXP) Says Interim Analysis Shows TNX-102 SL Unlikely to Demonstrate Statistically Significant Improvement, Enrollment Stopped
July 23, 2021 4:57 PM EDTTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has decided to stop enrollment in the Phase 3 RALLY study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the management of fibromyalgia following an unblinded, pre-planned interim analysis by the Independent Data Monitoring Committee (IDMC) of the RALLY study. Based on interim analysis results of the first 50% (n=337) enrolled participants, the IDMC recommended stopping the trial for futility as TNX-102 SL is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall change from baseline in daily diary pain severity scores between those... More
